A once daily drug combination of sofosbuvir-velpatasvir for 12 weeks resulted in sustained eradication of several genotypes of the hepatitis C virus in 99% of patients in a clinical trial, according to a study in The New England Journal of Medicine. Read more and read the study abstract.